(Q34641082)

3 August 2017

The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS). (English)

1 reference

3 August 2017

1 reference

Rossella Parini

2

0 references

Roberto Giugliani

4

object named as

Roberto Giugliani

1 reference

3 August 2017

Simon A Jones

1

1 reference

3 August 2017

Paul Harmatz

3

1 reference

3 August 2017

Juanzhi Fang

5

1 reference

3 August 2017

Nancy J Mendelsohn

6

1 reference

3 August 2017

HOS Natural History Working Group on behalf of HOS Investigators

7

1 reference

3 August 2017

14 March 2013

1 reference

Molecular Genetics and Metabolism

3 August 2017

1 reference

3 August 2017

109

1 reference

3 August 2017

1

1 reference

3 August 2017

41-48

1 reference

The frequency of lysosomal storage diseases in The Netherlands.

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Cumulative incidence rates of the mucopolysaccharidoses in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Mild form of Hunter's syndrome: clinical delineation based on 31 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

A clinical study of 77 patients with mucopolysaccharidosis type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Natural progression of neurological disease in mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Initial report from the Hunter Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Psychosocial aspects of constitutional short stature: social competence, behavior problems, self-esteem, and family functioning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Quality of life in short adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2013.03.001

10.1016/J.YMGME.2013.03.001

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference